Zepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly says [Video]

(NEXSTAR) – New injectable drugs like Ozempic, Wegovy, Mounjaro and Zepbound have grown extremely popular with people seeking to lose weight. They’re so in demand that most varieties are listed in short supply by the Food and Drug Administration – and that may be the case for the foreseeable future.

Eli Lilly, the pharmaceutical company behind Zepbound and Mounjaro, told NBC News supply issues could last into 2025.

“It is the demand that’s causing this. We are working so hard every day to make sure that we increase that capacity as fast as we can to get these medications in patients’ hand,” Rhonda Pacheco, Eli Lilly’s group vice president for diabetes and obesity, said in an interview with NBC.

Zepbound and Mounjaro are the same drug, tirzepatide, but they are marketed under two different names. Zepbound is FDA-approved to treat obesity, while Mounjaro is approved to treat diabetes.

Almost all dosages of both brand names are listed as “currently in shortage” by the FDA. Only one dosage …